drugset / Trial / NCT00663195

Effects of Spironolactone on Matrix Metalloproteinases (MMPs) in Heart Failure

NCT00663195

Phase 4 Completed 16 enrolled Tottori University Hospital
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to evaluate the effects of spironolactone on circulating MMP levels and insulin resistance in patients with chronic heart failure.

Timeline

Start
2004-01
Primary completion
Completion
2005-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Spironolactone Small molecule 25 mg
Background Furosemide Other / unclassified 20 mg

Indications